A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Omiganan (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Sponsors Cutanea Life Sciences
- 23 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 30 May 2017 This trial was completed in Sweden, according to European Clinical Trials Database.
- 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.